Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,041.51
-38.85 (-3.60%)
At close: Jan 5, 2026, 4:00 PM EST
1,045.77
+4.26 (0.41%)
Pre-market: Jan 6, 2026, 9:10 AM EST
Eli Lilly Revenue
Eli Lilly had revenue of $17.60B in the quarter ending September 30, 2025, with 53.87% growth. This brings the company's revenue in the last twelve months to $59.42B, up 45.41% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$59.42B
Revenue Growth
+45.41%
P/S Ratio
15.75
Revenue / Employee
$1,264,251
Employees
47,000
Market Cap
932.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
| Dec 31, 2018 | 21.49B | 1.52B | 7.61% |
| Dec 31, 2017 | 19.97B | -1.25B | -5.88% |
| Dec 31, 2016 | 21.22B | 1.26B | 6.33% |
| Dec 31, 2015 | 19.96B | 343.10M | 1.75% |
| Dec 31, 2014 | 19.62B | -3.50B | -15.13% |
| Dec 31, 2013 | 23.11B | 509.70M | 2.25% |
| Dec 31, 2012 | 22.60B | -1.68B | -6.93% |
| Dec 31, 2011 | 24.29B | 1.21B | 5.25% |
| Dec 31, 2010 | 23.08B | 1.24B | 5.68% |
| Dec 31, 2009 | 21.84B | 1.46B | 7.19% |
| Dec 31, 2008 | 20.37B | 1.74B | 9.33% |
| Dec 31, 2007 | 18.63B | 2.94B | 18.75% |
| Dec 31, 2006 | 15.69B | 1.05B | 7.14% |
| Dec 31, 2005 | 14.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
LLY News
- 22 hours ago - Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down. - Market Watch
- 3 days ago - Top 15 High-Growth Dividend Stocks For January 2026 - Seeking Alpha
- 5 days ago - In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s - Barrons
- 6 days ago - Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump - Reuters
- 10 days ago - Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January - Seeking Alpha
- 12 days ago - GLP-1 weight-loss pills set to reshape US food demand in 2026 - Invezz
- 13 days ago - Focus: Lilly, Novo lock horns in India's obesity drug race - Reuters
- 13 days ago - US health agency to expand access to GLP-1 weight-loss drugs - Reuters